Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

    ... agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide . For patients no longer benefitting from these agents, there ...

    Research Article last updated 01/26/2017 - 10:36am.

  2. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

    ... manifested as erythroid hypoplasia. P53 antagonism by lenalidomide or other therapeutics such as antisense oligonucleotides, ...

    Research Article last updated 01/26/2017 - 10:06am.

  3. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... harboring TP53 mutation do not show a good response to lenalidomide therapy. In general, the results of this study show that ...

    Research Article last updated 02/01/2017 - 8:15am.

  4. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... Purpose:  Lenalidomide has been shown to have single agent activity in indolent ... The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  5. Patient Trusts Her Instincts in Finding the Right Treatment

    ... with vitamin B12 and B6. Months later I began lenalidomide (Revlimid®) but after six months, no improvement was seen and ...

    Patient Chronicle last updated 05/10/2018 - 11:01am.

  6. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... for ESA- refractory or relapsed patients include lenalidomide , alone or in combination with ESAs; oral azacitidine ; ...

    Research Article last updated 12/09/2016 - 2:50pm.

  7. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... failed to respond to or progressed on treatment with lenalidomide j. Eastern Cooperative Oncology Group (ECOG) performance ... Treatment with cytarabine at any dose, lenalidomide , or any other therapy targeted for the treatment of MDS (other ...

    Clinical Trial last updated 05/04/2018 - 3:53pm.

  8. Recent developments in bone marrow transplants

    ... marrow transplantation. A prolonged course of lenalidomide (Revlimid, Celgene) maintenance following autologous ...

    Article last updated 11/16/2016 - 2:56pm.

  9. I Was Alone With MDS Until I Connected With Others on Social Media

    ... count was so low. I started a regimen of an oral lenalidomide , (Revlimid®). My oncologist then dismissed me without ... counts increased from injections and I continued taking  lenalidomide. I was naïve in thinking lenalidomide would not have side effects ...

    Patient Chronicle last updated 04/26/2018 - 9:40am.

  10. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... with less than 50 % response, lasting 2 years. Aza and lenalidomide (Len) have a potential synergistic effect. ViLen-01 phase IIa ...

    Research Article last updated 09/13/2016 - 2:47pm.